Y
HN Search
Hacker News Search
new
|
comments
|
top
|
jobs
notlob
searching PlanetScale…
1.
▲
2.
▲
3.
▲
4.
▲
5.
▲
6.
▲
7 ms
·
1.
▲
by
notlob
8y ago
[deleted, this was a total overshare]
2.
▲
How Technology Grows (a restatement of definite optimism)
(danwang.co)
2 points
by
notlob
8y ago
|
0 comments
3.
▲
by
notlob
8y ago
Yeah, exactly. The linked article quotes parts of the suit that specifically say "nicotine salts" which I think is suggestive that this may be a big part of the case.
4.
▲
by
notlob
8y ago
> JUUL is like any other nicotine alternative (e.g. gum) Not exactly so, a distinguishing feature of Juul is that the nicotine provided is formulated as a salt rather than as a free base.
5.
▲
Millions of educated, experienced workers are tossed aside by a strong economy
(washingtonpost.com)
89 points
by
notlob
8y ago
|
123 comments
6.
▲
by
notlob
8y ago
What parts of this would you expect to be of interest for startups outside of digital, specifically biotech?
7.
▲
George Hotz is on a hacker crusade against the ‘scam’ of self-driving cars
(theverge.com)
14 points
by
notlob
8y ago
|
1 comments
8.
▲
by
notlob
8y ago
I see where you're coming from now. ABX (antibiotics) are a bit unique. New ABX are sparingly profitable because they are usually incremental developments instead of new classes of compounds. A new class would be lucrative. I see t
9.
▲
by
notlob
8y ago
Public funds are used up to proof of concept and sometimes early tox/CMC (often through a CRO), but the bulk of the funding for trials comes from industry.
10.
▲
by
notlob
8y ago
UPenn and Novartis brought Kymriah to market and Kite brought Yescarta to market. Universities can be great for discovery and sponsored research, but they are not leading the work needed to get to market and they are certainly not funding i
11.
▲
by
notlob
8y ago
This is an inaccurate portrayal of the pharmaceutical industry. Take CAR-T as one obvious counterexample.
12.
▲
by
notlob
8y ago
Post-AIA, US utility patents (including APIs, biologics, methods of manufacture/use, etc.) are 20 years with possible adjustments to term length.
13.
▲
by
notlob
8y ago
I’m not in IT tech, last job search a couple years ago took about a year and I’m starting another that’ll likely take as long. It’s just fantastic to me that multiple people could simultaneously find employment on short notice. It’s a world
14.
▲
by
notlob
8y ago
There could be a good blog post in that? Planning to do right by your employees, even when times are hard. (Also, I can't imagine what it'd be like for jobs to be easy to find!)
15.
▲
by
notlob
8y ago
What happened with the people you had to let go? Did you prioritize rehiring them once your ship was righted or help them find new positions?
16.
▲
by
notlob
8y ago
> If they don't, you have a job you otherwise wouldn't have had. No, you have a job for as long as you're able to keep your lie secret. Once the lie comes out, even if it's X years down the road, you're terminat
17.
▲
by
notlob
8y ago
> It also depends of your tolerance of rednecks, prudes, puritans, and ignorant people (which exist everywhere in the world, but have particularly large concentrations there). FYI, using "redneck" as a pejorative, as in this co
18.
▲
by
notlob
8y ago
> > > They timed production to maximize federal tax credits for US consumers. This is what is confusing me: if the credits are timed to domestic sales (so international sales don’t affect the timing of the tax credit phase out) w
19.
▲
by
notlob
8y ago
Can you quote the text here? For the life of me I can’t find the section you’re referencing. I’ve heard the “timing production to match tax credit” thing before and it doesn’t make sense to me, hence why I’m trying to track down the primary
20.
▲
by
notlob
8y ago
Can you clarify, did Tesla announce this, or are you announcing this?
21.
▲
by
notlob
8y ago
I wasn’t intending to advance an argument, merely present that as a biotech entrepreneur in the process of forming a new company I for one like many of the changes in this proposal. I completely get why software people take umbrage with pat
22.
▲
by
notlob
8y ago
One biotech person's perspective is that these are changes in the right direction. Things were certainly not perfect in the pre-AIA era, but post-AIA and recent court decisions have had many negative impacts on our industry, particular
23.
▲
Elon Musk drawn into copyright dispute with potter
(amp.theguardian.com)
1 points
by
notlob
8y ago
|
0 comments
24.
▲
by
notlob
8y ago
> The reality is that HSR isn't cost-effective if the trip takes more than about 5 hours. Can you expand on that? It's not obvious to me.
25.
▲
by
notlob
8y ago
This appears to simply be a copyright violation based on the demand letter.
26.
▲
How blood-testing startups are pitching themselves after the Theranos scandal
(marketwatch.com)
1 points
by
notlob
8y ago
|
0 comments
27.
▲
by
notlob
8y ago
Both of your examples have transmissions, they are however a single gearing ratio (“reduction gear”). EV conversions also frequently use a multi-gear transmission, as did the original Tesla Roadster IIRC.
28.
▲
by
notlob
8y ago
Theranos was tight lipped on the tech. An alternative interpretation is that there was insufficient information on the tech at that moment for knowledgeable people to weigh in on, other than to observe that this is a difficult problem and a
29.
▲
by
notlob
8y ago
An interesting observation is that medman77 would seem to be particular about FDA clearance vs approval, which is one sign of someone who does know what they’re talking about.
30.
▲
by
notlob
8y ago
In risk management for the medical devices I’ve worked on, we account for users and patients not following instructions during the design process. “You’re holding it wrong” is literally something we account for. From my perspective Tesla ha
More ›